Cargando…
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies
We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrom...
Autores principales: | Azim, Hamdy A, Bahr, Sherif Ahmed, Kamal, Nermine Shawky, Koura, Mohamed Adel, Tolba, Rehab, Gad, Heba Abdelmoneem, Morsy, Ahmad, Attia, Hossameldin Mohsen, Iskander, Ibraheem, Hammad, Ahmed, Hemed, Mohammed Farouk, Abdallah, Mohammed Fathy, Sadek, Kareem Ahmed, Taha, Alaa Hamdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855003/ https://www.ncbi.nlm.nih.gov/pubmed/24324529 http://dx.doi.org/10.3332/ecancer.2013.378 |
Ejemplares similares
-
Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011) -
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017) -
Rasburicase-Induced Methemoglobinemia
por: Ahmed, Moeed, et al.
Publicado: (2021) -
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
por: Cammalleri, Lisa, et al.
Publicado: (2007) -
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
por: Dinnel, Jennifer, et al.
Publicado: (2015)